Glaukos

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. 

CEO
Thomas William Burns
CEOThomas William Burns
Employees
1,094
Employees1,094
Headquarters
Aliso Viejo, California
HeadquartersAliso Viejo, California
Founded
1998
Founded1998
Employees
1,094
Employees1,094

GKOS Key Statistics

Market cap
7.84B
Market cap7.84B
Price-Earnings ratio
-40.56
Price-Earnings ratio-40.56
Dividend yield
Dividend yield
Average volume
1.02M
Average volume1.02M
High today
$135.26
High today$135.26
Low today
$130.04
Low today$130.04
Open price
$135.26
Open price$135.26
Volume
308.79K
Volume308.79K
52 Week high
$146.75
52 Week high$146.75
52 Week low
$73.16
52 Week low$73.16

Stock Snapshot

Glaukos(GKOS) stock is priced at $133.42, giving the company a market capitalization of 7.84B. It carries a P/E multiple of -40.56.

On 2026-05-11, Glaukos(GKOS) stock moved within a range of $130.04 to $135.26. With shares now at $133.42, the stock is trading +2.6% above its intraday low and -1.4% below the session's peak.

Trading activity shows a volume of 308.79K, compared to an average daily volume of 1.02M.

Over the past 52 weeks, Glaukos(GKOS) stock has traded between a high of $146.75 and a low of $73.16.

Over the past 52 weeks, Glaukos(GKOS) stock has traded between a high of $146.75 and a low of $73.16.

GKOS News

Simply Wall St 3d
Glaukos Is Up 15.7% After Raising 2026 Sales Guidance And Expanding Ophthalmic Portfolio – What's Changed

In late April 2026, Glaukos Corporation reported first‑quarter 2026 sales of US$150.57 million, a rise from US$106.66 million a year earlier, alongside a net lo...

Glaukos Is Up 15.7% After Raising 2026 Sales Guidance And Expanding Ophthalmic Portfolio – What's Changed
Simply Wall St 6d
A Look At Glaukos Valuation After Raised 2026 Sales Guidance And Strong First Quarter Revenue

Glaukos (GKOS) is back in focus after raising its 2026 net sales guidance to a range of US$620 million to US$635 million and reporting first quarter sales of US...

A Look At Glaukos Valuation After Raised 2026 Sales Guidance And Strong First Quarter Revenue
TipRanks 7d
Glaukos Highlights Growth Strategy in Interventional Eye Care

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

93%

of 14 ratings
Buy
92.9%
Hold
7.1%
Sell
0%

People also own

Based on the portfolios of people who own GKOS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.